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Abstract
Background: Targeted delivery of pharmaceutical agents into selected populations of CNS (Central Nervous
System) neurons is an extremely compelling goal. Currently, systemic methods are generally used for delivery of
pain medications, anti-virals for treatment of dermatomal infections, anti-spasmodics, and neuroprotectants.
Systemic side effects or undesirable effects on parts of the CNS that are not involved in the pathology limit
efficacy and limit clinical utility for many classes of pharmaceuticals. Axonal transport from the periphery offers a
possible selective route, but there has been little progress towards design of agents that can accomplish targeted
delivery via this intraneural route. To achieve this goal, we developed a tripartite molecular construction concept
involving an axonal transport facilitator molecule, a polymer linker, and a large number of drug molecules
conjugated to the linker, then sought to evaluate its neurobiology and pharmacological behavior.
Results: We developed chemical synthesis methodologies for assembling these tripartite complexes using a variety
of axonal transport facilitators including nerve growth factor, wheat germ agglutinin, and synthetic facilitators
derived from phage display work. Loading of up to 100 drug molecules per complex was achieved. Conjugation
methods were used that allowed the drugs to be released in active form inside the cell body after transport.
Intramuscular and intradermal injection proved effective for introducing pharmacologically effective doses into
selected populations of CNS neurons. Pharmacological efficacy with gabapentin in a paw withdrawal latency
model revealed a ten fold increase in half life and a 300 fold decrease in necessary dose relative to systemic
administration for gabapentin when the drug was delivered by axonal transport using the tripartite vehicle.
Conclusion: Specific targeting of selected subpopulations of CNS neurons for drug delivery by axonal transport
holds great promise. The data shown here provide a basic framework for the intraneural pharmacology of this
tripartite complex. The pharmacologically efficacious drug delivery demonstrated here verify the fundamental
feasibility of using axonal transport for targeted drug delivery.
Background
The direct distribution of medications to specific target
tissues in the central nervous system (CNS) is an attrac-
tive objective for the treatment of problems such as
local pain or dermatomal viral infection. When systemic
drug delivery is used to treat a symptom affecting a
small segment of the nervous system (such as pain in a
single dermatome) conventional drug delivery methods
can be highly inefficient because they place most of the
dose in non-neuronal tissues throughout the body and
in areas of the CNS that do not need treatment. Dose
limitation that hinders efficacy often arises from the
concentration of the drug in non-target tissues. For
many compounds, this situation is aggravated because
access to tissues of the central nervous system is also
compromised by the relative impermeability of the
blood brain barrier.
The nervous system itself provides an alternative to
the vascular system or the cerebro-spinal fluid (CSF) -
the intra-axonal route. However, this has proven diffi-
cult to exploit. Methods using direct injection into
nerves [1], introduction of modified neurotropic viruses
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any medium, provided the original work is properly cited.[2], or delivery of neurotoxins such as tetanus toxin or
ricin [3,4] have been explored but each pose barriers to
routine clinical use. Direct injection may damage nerves,
neurotropic viruses expose the recipient to direct
damage or the risk of recombination with wild type
virus, and toxins for nerve destruction have limited clin-
ical roles. Phage display has been used to generate syn-
thetic peptides to promote axonal transport [5], but it
has not been clear how to exploit this.
Retrograde axonal transport of exogenous molecules
from the periphery to CNS neuronal cell bodies is long
established [6] and is one of the methodological bases for
mapping neuroanatomical pathways [7-9]. The underly-
i n gp h y s i o l o g i c a lb a s i so ft h i sp r o c e s sa n di t sb i o c h e m i s -
try are increasingly well understood [10-19]. However,
although axonal transport for drug delivery has been pro-
posed previously [20-24], little or nothing is known about
the major features of this biological system from the
point of view of approaching it pharmacologically and
there has been no agent demonstrated capable of accom-
plishing a pharmacological effect via this route.
Pharmacological entrainment of axonal transport is
acknowledged as a highly desirable objective since it
would allow for targeted antiviral, antineuropathic or
regenerative treatments to segmentally selected ganglion
or CNS cells. We sought to clarify the pharmacology of
intraneural drug delivery and to design agents capable
of accomplishing therapeutic tasks by clinically applic-
able axonal transport methods employing intramuscular
injection and subsequent uptake by intact nerve endings.
We designed a novel tripartite molecular complex to
p r o v i d eaf l e x i b l ea r c h i t e c t u r e capable of achieving this.
We now report on this class of pharmacological agents
for selective targeted access and transport through the
n e r v o u ss y s t e ma n dd e m o n s t r a t et h a ti ti sc a p a b l eo f
achieving therapeutic efficacy. The system provides a
versatile platform for many different therapies with the
same targeting requirements. The agents used are var-
ious forms of a tripartite complex composed of a first
moiety acting as an “axonal transport facilitator” (ATF),
an “amplifying polymer” (AP) second moiety acting to
achieve amplification of the fundamental event of synap-
tic endocytosis by carrying along multiple drug mole-
cules with each saturable uptake event, and a third
moiety composed of multiple copies of the therapeutic
molecule, reversibly linked to the polymer (Figure 1).
This novel molecular architecture allowed us to inde-
pendently explore and optimize general features and
constraints affecting the three major aspects of the pro-
blem - A) chemical synthesis, B) optimization of uptake
and transport, and C) intraneuronal drug efficacy after
transport.
We used a comprehensive array of biological, physical
and chemical assays in vitro and in vivo to characterize
and optimize the system. The studies are numbered [1]
to [23] corresponding to the summarized results table
(table 1).
A) We studied the synthesis and stability of the tripar-
tite and its components addressing the following ques-
tions: [study 1] Can tripartite molecules be constructed
chemically to preserve efficient adsorptive endocytosis
when loaded with large numbers of conjugated drug
molecules? [study 2] What are the upper size limits for
the tripartite complex? [study 3] Can pharmacologic
activity be preserved for small molecules released from
the tripartite complex under intracellular conditions?
B) We analyzed interactions with axon terminals and
the intra-axonal environment that would affect design of
the tripartite by investigating the following questions:
[studies 4, 5 & 6] - How do polymer size, molecular
charge, and hydrophilicity affect the efficiency of uptake
into neurons? [studies 7, 8 & 9] - What is the relative
efficiency of physiologic ATFs (axonal transport facilita-
tors) when compared to non-physiologic ATFs for
uptake and transport? Can purely synthetic ATF’sb e
produced by phage display techniques that will be more
effective than physiologic ATFs? Will use of colchicine -
an inhibitor of axonal transport serve to verify interpre-
tations? [studies 10,11,12,13,14 & 15]C a nas m a l li n t r a -
muscular or intradermal injection cause significant
delivery into a selected set of neurons via intact unin-
jured axon terminals in normal tissues? Can this clini-
cally usable method of drug administration achieve high
intra-neuronal drug concentrations when compared to
the “cut neuron” methods used to introduce axonal
transport tracer molecules in some anatomical studies?
During axonal transport, if the pharmacologic agents are
sealed inside vesicles, will the drug or carrier be
Figure 1 Tripartite delivery vehicle.( a) The drug delivery vehicles
include a targeting element - the axonal transport facilitator or ATF
(blue sphere), and a polymer such as dextran (red repeating units)
that carry multiple drug molecules (purple). (b) They are designed
to be injected in muscle or skin and then travel via an “intraneural”
route to deliver the drug molecules to the cell body. (c) Late during
transport and on arrival in the cell body, lytic processes release the
active drug molecule by breakdown of the linker components.
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Page 2 of 26Table 1 Axonal transport experiments
Study Agent used Model Evaluation
method
Result Figure Impact
A Synthesis, function and stability
I Chemical synthesis
1 Dextran tripartites Chemical NMR, PLC, Mass
Spec
30% loading 2
a. CM dex standard
b. CM dex-amino upgraded
c. CM dex-lysine extended
d. WGA-CM dex
e. WGA-CM dex-valacyclovir
f. CM dex-gabapentin
g. WGA-CM dex-gabapentin 1 Validate chemical basis of
uptake amplification
2 Ferrite particle tripartites chemical MRI useful effect on T2 at
obtainable conc.
a. dex coated particles precip
b. periodate conjugation
c. affinity purification Validate assembly of
nanoparticulate carrier
d. DNA adhesion
e. relaxivity assessment test tube cast
gels
solenoid coil 7 Validate imageability in MRI
II Intracellular release and drug activation
3 valacyclovir BHK-Herpes plaque count control Establish cellular capability of
uptake and release
dex-val BHK-Herpes plaque count steric decrease in uptake
WGA-dex-val BHK-Herpes plaque count,
assay
improved delivery
B Interaction with Axon Terminals and Intra-axonal environment
III Effects of polymer, linker and drug
4 Dextran 10K symp gang fluor mic rapid uptake Evaluate effects of tripartite size
on uptake
Dextran 70K symp gang fluor mic slower uptake
5 Dextran-FITC neut symp gang fluor mic extensive uptake 3 Evaluate effects of tripartite
charge on uptake
Dextran-FITC pos symp gang fluor mic extensive uptake
Dextran-FITC neg symp gang fluor mic limited uptake
6 Acylation symp gang fluor mic no uptake Evaluate effects of
hydrophobicity on uptake
IV Effects of Axonal Transport Facilitator
7 WGA-FITC symp gang,
Campenot
fluor mic WGA and NGF well
transported
Comparability of physiologic
and non-phys ATF in vitro
NGF-TR symp gang,
Campenot
fluor mic WGA and NGF well
transported
4,17,18
8 Phage display Campenot pfu’s identification of synthetic
ATF
Phage display for generation of
synthetic ATFs
9 Transport inhibitor symp gang,
Campenot
fluor mic blocked by inhibitors of
transport
Confirmation of role of
microtubule based transport
V Effects of Intra-axonal Processing
10 Anti-gabapentin Ab gastroc/ant
tib - rat
excise, Ab stain delivery of gabapentin
antigenicity to DRG
Confirm delivery of gabapentin
antigenicity
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11 WGA-HRP axial - M.
fascicularis
HRP-TMB backlit small IM inj to enzyme in
cells in primates
5 Confirm that enzymatic
function survives transport
12 WGA-dex-mag gastroc -
rabbit
EM transport in axoplasm 6 Verify axonal transport
compartment
13 59-Fe WGA-dex-mag gastroc/ant
tib-rabbit
autoradiography gross sections Confirm intraneural transport of
particle tripartite
14 WGA-dex-mag gastroc/ant
tib-rabbit
MRI vs gel
chamber
non-lysis of particle 8,19 Confirmation of transport of
intact magnetite
15 WGA-dex-mag forearm-
rabbit
4.7T high res
MRI
demonstration of nerve
image
9 Confirmation of fast transport of
intact magnetite
C Targeting and pharmacological efficacy
VI Clinical target access
16 WGA-FITC hindlimb - rat excise, section, fl
mic
ventral horn &
intermediolateral
10 Assess access to relevant motor
& autonomic targets
WGA-dex-FITC hindlimb - rat excise, section, fl
mic
ventral horn &
intermediolateral
Dex-FITC hindlimb - rat excise, section, fl
mic
limited transport
17 WGA-FITC hindlimb - rat excise, section, fl
mic
DREZ lamina I and II 11 Confirm access to dorsal root
entry zone
WGA-FITC hindlimb - rat excise, section, fl
mic
DRG axon dendrite
18 WGA-FITC hindlimb - rat fluor mic, cell
count
good filling in DRG 12,13 Assess properties of access to
dorsal root ganglia
WGA-TRITC foot pad-rat fluor mic, cell
count
good filling in DRG
19 WGA-FITC hindlimb - rat fluor mic,
peripherin
nociceptors reached 14 Verify access to nociceptors
dextran-FITC hindlimb - rat fluor mic,
peripherin
no transport
VII Distinctive pattern of distribution relative to trans-vascular
20 125-I WGA forelimb/
hindlimb - rat
dissect, count saturable, time consistent,
selective
15 Characterize expected whole
body distrib
125-I NGF hindlimb - rat dissect, count differences in distribution
due to ATF
Evaluate effects of ATF on
distribution
59-Fe WGA-dex-mag forelimb - rat dissect, count large particles comparable Evaluate effects of large agent
size on distribution
21 131-I WGA gastroc/ant.
tib-rabbit
gamma camera
image
voxel size causes
averaging and inj site
bright
Examine local injection area
effects
22 14C-gbp-dex hindlimb - rat dissect, count minimal Validate delivery of therapeutic
dose
14C-gbp-dex-WGA hindlimb - rat dissect, count transported in high conc.
VIII Unique pharmacologic effects not obtainable by trans-vascular
23 gbp-dex-WGA foot pad/
hindlimb - rat
withdrawal
latency
prolonged decrease in
hyperalgesia
16 Validate pharmacological
efficacy
gbp-dex foot pad/
hindlimb - rat
withdrawal
latency
minimal 16
gbp foot pad/
hindlimb - rat
withdrawal
latency
minimal 16
gbp-dex-WGA cervical fat
pad - rat
withdrawal
latency
minimal 16
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ing long distances in the intracellular space of the
axons?
C) We investigated targeting and pharmacological effi-
cacy: [studies 16,17,18 & 19] - Which classes of clinically
useful sub-targets in the nervous system can be reached
by clinically convenient administration techniques? [stu-
dies 20 & 21] - What are the unique features of the
whole body pharmacologic distribution of intraneuronal
agents and how do size of the molecular complex and
selection of ATF affect the distribution? [studies 22 &
23] Can pharmacologically efficacious doses of drugs be
delivered and are they functional when delivered to the
interior of a cell rather than to its exterior surface?
Using a tripartite construct designed according to the
results of the investigations outlined above, we were
able to administer a small intramuscular injection with
1/300
th of the usual oral dose of gabapentin (half life 8
hours) and achieve a degree of neuropathic pain sup-
pression that could not be obtained with tolerable
amounts of oral therapy while extending the half life of
the drug by more than an order of magnitude.
Results
Results are summarized in table 1
Chemical synthesis and stability (aspect A)
Chemical entities (project I)
Effective synthesis with loading sufficient for amplifica-
tion [study 1] The synthesis strategy (Figure 2) achieved
attachment of drug to at least 30% of dextran mono-
mers for both gabapentin and valacyclovir. The 70,000
MW dextran has approximately 430 dextrose sub-units
so each Wheat germ agglutinin (WGA) molecule endo-
cytosed in these experiments delivered around 100
molecules of drug.
Particle based carriers can be delivered intraneuronally
[study 2] EDTA washing of dextran coated magnetite
particulates resulted in hydroxide free ferrites that were
non-reactive and preserved their superparamagnetic
properties during axonal transport. After conjugation of
an axonal transport facilitator to the dextran coat, they
were effectively endocytosed and transported intact
despite their (10-15 nm) size (size measured by electron
microscopy).
Intracellular release and drug activation (project II)
The stability of a drug is maintained through chemical
linkage and biological release [study 3] In the BHK
(Baby Hamster Kidney cell line) viral plaque reduction
experiments, free drug in the culture medium resulted
in plaque reduction by 96% at a dose of 5 micrograms/
Figure 2 Outline of conjugation and synthesis. A polymer such as dextran is first activated with cyanogen bromide to generate a carboxy
modified dextran that can be conjugated to linker molecules attached at each monomer. The linkers are then conjugated with drug molecules.
A second cyanogen bromide activation step is then carried out and followed by conjugation with an axonal transport facilitator molecule (ATF).
An affinity purification step is then used to obtain drug loaded polymer complexes with ATF attached.
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bound to dextran was required to achieve an equivalent
effect. However we observed nearly 100% plaque reduc-
tion using a dose of 5 microgram/well of tripartite
WGA-dextran-drug conjugate. This demonstrates that
the WGA efficiently promoted endocytosis of the tripar-
tite agents while dextran-drug alone was not readily
taken up by cells.
On chemical grounds, the carboxyl links binding drug
molecules to dextran should be hydrolyzed after endocy-
tosis. For valacyclovir (pharmacologically inactive), the
product of the hydrolysis is free and active acyclovir.
Therefore, the antiviral effect of the tripartite confirms
release of acyclovir from the tripartite carrier after
endocytosis.
Interactions with axon terminus and axonal processing
(aspect B)
Effects of polymer, linker and drug (project III)
Effects of polymer size on tripartite uptake into nerves
[study 4] For the two dextran sizes tested, the uptake
was faster for the smaller 10K molecular weight dextran
than for the larger 70K molecular weight dextran. How-
ever, uptake of the 70K molecule was more effective
from the point of view of drug delivery. This is because
each 70K dextran delivered more attached drug mole-
cules (100 drug molecules per 70K dextran polymer
chain as opposed to 14 drug molecules delivered on
each 10K dextran polymer chain).
With 10K dextran, there is extensive uptake within ten
minutes after application and washing. Similar levels of
uptake are seen with 70K dextran after 60 minutes. How-
ever the differential efficacy of uptake was not large
enough to outweigh the benefits of greater amplification
of uptake events achieved by using the higher capacity lar-
ger molecules for drug delivery. Since molecular loading
efficiency of the polymers was equivalent for various sized
dextrans, the increased drug delivery with increased mole-
cular size was linear. However, the losses in uptake effi-
ciency with larger molecules was not severe enough to
make them less effective overall. The consequence is that
although smaller dextran molecules were endocytosed
more avidly and rapidly than 70K based vehicles, more
drug molecules were still delivered by the 70K based vehi-
cles if a full hour was allowed to elapse after introduction
of the test agent. Larger molecule sizes were not tested.
Effects of charge on uptake and transport [study 5] The
overall charge of the complex had a large impact on effi-
ciency of uptake (Figure 3). There was virtually no uptake
into cultured neurons when the overall charge of the
complex was negative, and effective uptake occurred
when charge was neutral, or when overall charge was
positive. This finding parallels the natural movement of
positively charged ions into the negatively charged
internal milieu of the cell during depolarization. Similar
charge findings have been reported for liposomal drug
delivery systems [25].
Effects of side group mediated hydrophobicity on uptake
and transport [study 6] Acylation of FITC (fluorescein
isothiocyanate)-labeled, WGA-conjugated dextran to
make the molecules progressively hydrophobic led to
complete failure of uptake and transport. We assessed
various degrees of acylation and found that this effect
occurred even at very low ratios of acylation.
Effects of axonal transport facilitator (project IV)
Efficacy of physiologic, non-physiologic and synthetic
ATFs [studies 7,8,9] The Campenot chamber studies
demonstrated similar efficacy for Nerve growth factor
(NGF) and WGA for promoting uptake of the tripartite
carrying FITC (Figure 4). The phage display experiments
demonstrated that novel purely synthetic ATFs could be
discovered and then produced in vitro which not only
had equivalent efficiency for neuronal uptake, but which
could also be more efficiently sub-targeted to different
types of neuronal populations (e.g. general sensory, pain,
motor, autonomic).
When colchicine - an inhibitor of axonal transport -
was added to Campenot chambers, it blocked intra-axo-
nal movement of molecular complexes whose ATF was
derived from purely synthetic phage display techniques.
This confirms that the drug transport effect produced
by the synthetic phage display products achieved deliv-
ery by axonal transport.
Effects of intra-axonal processing (project V)
Survival of small chemical molecules linked to the tripar-
tite [study 10] When WGA-dextran-gabapentin was
used, cross staining with antibodies to gabapentin con-
firmed preserved antigenicity of the drug after axonal
transport of the tripartite, although this method could
not itself confirm that the drug was intact or active after
transport and release. Dextran-gabapentin with no con-
jugated WGA did not produce detectable gabapentin
antigenicity in the histological sections.
Large molecule access to spinal cord from intramuscular
injections [study 11] After small IM injections in muscle,
Figure 3 Effects of molecular charge on neuronal uptake and
transport.( a) lack of uptake of WGA-dextran-FITC after carboxyl
derivatization resulting in negative charge.(b) good uptake with
neutral charge from 50:50 carboxyl and amine derivatization. (c)
good uptake with positive charge from amine derivatization. Scale
bar is 120 μm.
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enzyme to label numerous motorneurons (Figure 5) in
our primate model. Enzymatic activity of the horseradish
peroxidase survived any hypothetical lysosomal degrada-
tion during transport and yielded product distributed
throughout the neuron. Both epaxial and hypaxial mus-
cles proved an effective route to reach spinal cord
quickly (several hours) with no apparent difference in
delivery of intact enzyme via axons despite the differ-
ence in distance of transport. The labeled spinal cord
motor neuron pool for these axial muscles had greater
longitudinal extent among spinal cord segments than
for appendicular muscles. These findings are consistent
with previous reports concerning WGA [26] and NGF
[27] and their intramuscular introduction [28,29].
The rate of transport appeared to be consistent with
time scales predicted by literature values of 30-100 mm/
day [30]. Overall the area of spread of injectate in the
spinal cord was limited to a few millimeters, although
the distribution of the epaxial muscle spinal cord motor-
neuron pool extended over several centimeters. This
appeared to demonstrate that a group of neurons near
each other in the spinal cord innervated a group of
fibers in epaxial muscle that are close together despite
the wider extent of the overall motor neuron pool.
Intact transport of targeted nanoparticles by intact axon
termini [studies 12, 13, 14, 15] Electron microscopy
showed appropriately sized ferrites within the axon,
more than three centimeters from the WGA-dextran-Fe
injection site (Figure 6). The appearance of the ferrites
in endosomes was similar to what has been seen in stu-
dies of similar agents in other tissues [31], but in this
case the particles were restricted to the axonal stream.
The autoradiographic studies demonstrated sciatic nerve
radioactivity and so provided similar evidence that the
magnetite containing particles were transported in
nerves.
The relaxivity experiments (Figure 7) taken together
with distribution studies showed that the concentration
of magnetite delivered to the axon by the tripartite was
sufficient to affect the T2 relaxation rate of nerve. The
observation of a decrease of T2 relaxation time in
nerves transporting superparamagnetic nanoparticles in
both the micro-MRI nerve channel studies (Figure 8)
and in the high resolution MRI experiments (Figure 9)
confirmed that the carrier particles were not degraded.
Any hydrolysis of the sub-domain sized particles would
Figure 4 Axonal Transport of NGF and WGA in Campenot Chambers. Top panel shows a transmission image of the central and side
compartments of a Campenot chamber. WGA-FITC or NGF-Texas Red were added to the side compartment and left overnight. At higher
magnification, the “red series” of panels are fluorescent images obtained from the arrowed areas of the chamber following NGF-TR
administration. Similarly, the “green” series of panels shows fluorescent images taken of the chambers following WGA-FITC administration. The
left most panels in both series show uptake of fluorescence in cell bodies derived from the axonal transport of these labeled ATFs.
Figure 5 Axonal transport to spinal cord neurons
(longitudinal).( a-c) Magnified, back illuminated view of an
individual motor neuron in an oblique longitudinal section through
a portion of the ventral horn of the spinal cord (Macaca fascicularis),
and seen at lower magnification in figures (b) and (c). The dark
orange material seen inside the cell and filling the cell body and
dendritic processes is the product of a chemical reaction carried out
by an administered enzyme, horseradish peroxidase. To introduce
this exogenous enzyme into the cell, it was conjugated to WGA, an
ATF (axonal transport facilitator), then injected into a muscle
innervated by the axons which arise from these neuron cell bodies.
Scale bars (a)=5 0μm, (b) = 200 μm, (c) = 400 μm.
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relaxation time in nerve as transport progressed. The
relaxivity effect far exceeded that which would result
from free iron or ferritin at the doses administered.
The WGA-dextran-magnetite experiments in rabbits
confirm other reports [32] that particles of 5-15 nm are
endocytosed and transported by intact nerve endings.
Some studies have suggested that nerve injury is
required for the transport of larger particles [33], but
this result suggests that intact neurons will indeed
transport large (up to 15 nm) multi-molecular aggre-
gates or “transport particles” after intramuscular injec-
tion when the particles are well solvated.
C. Targeting and pharmacological efficacy (aspect C)
Clinical target access (project VI)
Targeted Access to Clinically Relevant Neuronal Sub-popu-
lations [studies 16, 17, 18, 19] Intramuscular injection of
the tripartite WGA-dextran-FITC produced labeling of
alpha motor neurons in the ventral horn and autonomic
neurons in the intermediolateral cell column (Figure 10).
We also observed good filling of proximal sensory neuron
processes (axons) in the dorsal root entry zone and in
lamina I and II of the dorsal horn of the spinal cord (Fig-
ure 11). Injection of foot pad and multiple hind limb
muscle each resulted in labeling of less than 50% of gang-
lion cells, but injection of both muscle and skin resulted
in filling of nearly 90% of dorsal root ganglion (DRG)
cells (Figures 12 &13). In clinical use, the objective will
typically be to reach specific sub-populations rather than
filling an entire ganglion per se, so these results support
the expectation that a large fraction of cells in a e.g. a
subpopulation innervating a single muscle or patch of
skin can readily be reached.
Figure 6 Intra-axonal location of transported agents.( a)
Electron micrograph of rabbit tibial nerve four days after injection
of the gastrocnemius muscle with ferrite-WGA tracer. (b) magnified
view of a vesicle seen in (a) to 195,000×. (ly) lysosomal vesicle, (fp)
small particles transporting on microtubules (mi), (ep) larger
particles in vesicles.
Figure 7 T2 relaxivity of hydroxide free magnetite preparations. T2 relaxivity curves for polyacrylamide “tissue” gels polymerized with
uniform distributions of various dextran coated magnetite particle preparations. Relaxivity is compared with the concentration of particles in the
each gel preparation as assessed by ferrozine assay of iron content after the imaging. 1/T2 was measured in a 4.7Tesla Sisco MR spectrometer.
At concentrations comparable to what was achieved in nerve by axonal transport, a T2 below 30 milliseconds would be expected for any of
these particle preparations. D10 = 10,000 MW dextran coating, D40 - 40,000 MW, D70 - 70,000 MW, Mgn = magnetite, WGA is wheat germ
agglutinin, Seph II - sepharose separated to reduce contamination of magnetite by non-superparamagnetic ferrites.
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that many of the DRG sensory neurons that were
accessed were C-fiber nociceptor cells (Figure 14). This
helps confirm that this method of delivery does reach a
selected subset of nociceptors that correlates specifically
with the selected site of injection. The ATF played a
major role since no detectable fluorescence was
observed when dextran-FITC without ATF was adminis-
tered in these experiments.
Distinctive pattern of distribution relative to trans-vascular
(project VII)
Unique distribution with high fraction of drug reaching
neuronal targets [study 20] In the whole body distribu-
tion studies with small calf muscle injections, the con-
centration of [
125I]-WGA detected in relevant ipsilateral
peripheral nerve and dorsal root ganglia reached six
times systemic concentrations (Figure 15). The detected
concentration in relevant nerve and ganglia (the sciatic
nerve and DRGs in continuity with the sciatic nerve)
demonstrated saturability and transport time consistent
with other reports [34]. Activity in spinal cord was less
than in nerve or DRG but did reach twice systemic con-
centrations when higher concentrations of injectate
were used.
There was no significant activity detected in contralat-
eral nerve and DRGs nor in ipsilateral nerves, ganglia, or
spinal cord related to cervical, thoracic, or higher lumbar
Figure 8 Microscopic MRI evaluation of sciatic nerve magnetite
contrast effect. Microscopic MRI image of sciatic nerve in
calibrating gel chamber in anaesthetized rabbit. The experimental
set up is detailed in Figure 19. The wall of the silastic cuff was
opened and placed surgically around the sciatic nerve. Serial images
with a 2 cm surface coil allows for measurement of the relative T2
intensity of the sciatic nerve by comparison with the T2 of the
calibration gels in the three surrounding chambers with the elapse
of 8 hours between the pre-injection image and the post-transport
image. The injection was carried out immediately following the pre-
injection image. The T2 of the sciatic nerve decreases relative to the
calibration chambers as axonal transport of the WGA-dextran-
magnetite agent progresses. Scale bar is 4 millimeters.
Figure 9 Median nerve contrast study by solenoid coil high resolution, high field MRI. All images are from a single image slice of rabbit
upper arm. Image (a) is collected with a STIR (short tau inversion recovery) sequence which suppresses signal from fat - it reduces the marrow
signal (6), and also identifies structure (1) as the median nerve[44], structure (7) as the ulnar nerve, structure (8) as the flow void of he brachial
artery and structure 9 as the flow void of the basilic vein. Images (b)&( c)are colorized spin echo studies obtained at 90 minutes and 360
minutes after injection, respectively. Note that the marrow (3) appears shifted out the humerus (partially overlapped dark circle) by chemical shift
effects. The shift at 4.7 Tesla is 1.85 millimeters. Similar shifts are seen at (4), and serve at (5) to leave two bright structures in a gap between
triceps and biceps. (a-m), (b-m), (c-m) are magnified views of the space between the biceps and triceps on the medial aspect of the upper arm.
Structure (2) is a small amount of fatty tissue that is actually located on the inferior left surface of the brachial artery, but chemical shift has
placed its fat image into the midst of the basilic vein. Structure (2) disappears in the STIR image due to fat suppression. Based on this
identification, the median nerve (1/1a) is compared to the non-neural structure (2/2a) and is seen to lose intensity in the four and half hour
interval between images (b) and (c) reflecting transport of the WGA-magnetite contrast agent injected in the forearm flexor muscles [24]. The
image conspicuity of this structure was measured by multiplying its volume times the intensity in grayscale and this reveals a decrease of 52%
in the 270 minute interval. Scale bars are 6 mm for (a), (b), and (c) and 3 mm for (am), (bm) and (cm).
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were in liver and kidney but these apparently reflected
metabolized iodine lost from the compound.
NGF showed less transport to spinal cord than was
seen for WGA consistent with selective uptake of NGF
by sensory and autonomic nerves. Detection of activity
due to [
59Fe]-WGA-dextran at other systemic sites was
even less than for WGA or NGF alone.
Considerable amounts of drug remained in the axon
itself at the time points sampled. It is known that para-
nodal complexes of Schwann cells at the Nodes of Ran-
vier can endocytose materials from the axoplasm [35].
This may account for a peri-axonal depot effect with
drug being cleared to the para-nodal complexes and
then subsequently being re-released. Further studies will
be needed to clarify this issue.
Site of injection retains high amount of injectate [study
21] The regional view provided by the [
131I]-WGA
gamma camera studies demonstrates that the total
amount of the injectate remaining at the site of injection
can be large when compared to the amount in the small
volume of the nerve. In part, this reflects the fact that
WGA adheres to muscle cell membranes [36] as well as
being taken up by adsorptive endocytosis at nerve ter-
mini. This also explains a depot effect whereby addi-
tional amounts of the compound continue to be
introduced into the axonal stream over a period of sev-
eral days.
Pharmacologically efficacious drug amounts were deliv-
ered [study 22] The tripartite assemblage with [
14C]-
labeled gabapentin produced activity levels for gabapen-
tin in ipsilateral neurons of more than 600 times greater
than background while counts remained at background
levels in contralateral neurons. This demonstrated the
localizing effect of injection of polymer-bound drug con-
jugated to an axonal transport facilitator, and also
allowed us to estimate the drug concentration achieved
based on the specific activity of the [
14C]-labeled
gabapentin.
Pharmacologic effects of ATF mediated delivery not
obtainable by trans-vascular agents (project VIII)
Prolonged suppression of hyperalgesia [study 23] In the
hyperalgesia experiments a single injection with the tri-
partite agent reduced the hyperalgesia (p < 0.05 in eight
out of the nine comparisons of treatment versus con-
trol) for at least four days after injection (Figure 16).
The total dose was 0.375 mg/kg using the novel intra-
neural transport method compared to 120 mg/kg total
d o s eo r a l l yf o rf o u rd a y so fthe usual human oral dos-
ing. Prolonged efficacy may have been due to a depot
effect in muscle, slow redistribution from axon and
Schwann cells to nerve cell body, slow clearance from
inside the nerve, or preemptive blocking of newly pro-
duced receptor molecules en route from ribosome to
cell surface.
Discussion
We have demonstrated through a comprehensive series
of chemical, radiological in vitro,a n din vivo biological
studies that axonal transport is a valid route for drug
delivery when a tripartite (ATF-polymer-drug) complex
is used. We have used these studies to exemplify in vivo
a prolonged pharmacologically effective delivery of an
analgesic molecule leading to sustained significant
response in a standard nociceptive model.
Routine oral delivery of gabapentin results in clinical
efficacy for pain relief when blood levels reach 100 μM.
Gabapentin not only crosses the blood brain barrier but
is subject to some active concentration [37,38]. It is rea-
sonable to hypothesize, therefore, that clinically
Figure 10 Axonal transport to spinal motor neurons and
autonomic neurons.( a) Section of rat spinal cord showing
retrogradely transported WGA-FITC in the motor neuron cell bodies
(v) and in cells in the autonomic intermediolateral cell column (i).
(b) magnified view of motor neurons seen in (a). Scale bars (a)=
120 μm, (b)=3 0μm.
Figure 11 Dorsal root entry zone access by transported agents.
Section of spinal cord showing retrogradely transported NGF-TR
(Nerve Growth Factor - Texas Red) in the dorsal horn. (a+b) The
ipsilateral and contralateral dorsal horn viewed using darkfield
microscopy. (c+d) The same fields as in a+b viewed using
fluorescence microscopy. The arrow heads delineate the area of
DREZ lamina I and II where the proximal axons of the dorsal root
ganglia cells terminate on nociceptor neurons. Scale bars = 120 μm.
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would need to produce similar concentrations near the
internal cell surface of accessed neurons to achieve simi-
lar pharmacological efficacy.
In this model, histological estimates of the ratio
between the estimated intracellular volume of the
accessed neurons (InCvol) and the actual volume of the
entire dorsal root ganglion (DRGvol) provide a correc-
tion factor (InCvol/DRGvol) that allows for conversion
of total DRG concentration into estimated intracellular
concentration in the accessed neurons.
When these considerations were employed, our counts
of delivered [
14C] suggested delivery of gabapentin at
intracellular doses equal to or greater than 100 μM.
These in vivo [
14C]-gabapentin studies therefore showed
that this technology can deliver drugs to target neurons
at pharmacologically efficacious doses using 1/300
th of
the oral dose that would be required to achieve the
same intracellular concentration in target cells.
In addition, this system resulted in a ten fold increase
in effective half life relative to oral administration. This
appears to be because of the unique dynamics of this
delivery mechanism. This involves both a muscle
injection site depot effect for the large tripartite com-
plexes and a prolonged stream of delivery to the neuron
from the axon and its associated paranodal complexes.
Use of the tripartite vehicle made it possible to use a
selected axonal transport facilitator to cause transport of
large numbers of drug molecules and to recover the
pharmaceutical effect of the drug after delivery to its
target. By varying the polymer backbone length and by
use of various linker chemistries, it is possible to accom-
modate therapeutic molecules with a wide variety of dif-
ferent sizes and physico-chemical properties.
In this set of experiments, neither systemic delivery of
the agent by a subcutaneous route nor administration of
free drug alone to the affected limb had any significant
therapeutic effect. Although dextran can itself weakly
promote axonal transport [39], the use of dextran/drug
with no ATF showed only limited effect in occasional
animals and was in no case statistically significant. This
takes advantage of the greatly improved efficiency of tar-
geted adsorptive endocytosis - the tripartite complexes
specifically adhere to markers exposed on the external
surface of the axon terminus at sites destined to be
drawn into the interior of transport vesicles. These mar-
kers can be used in the phage display system to develop
new purely synthetic, non-viral ATFs to offer selectivity
for target neuron sub-types. The system is also applic-
able for introducing DNA to the neuronal nucleus with-
out the risks of viral transfection systems.
It had not been clear in the past whether gabapentin
acts inside nerve cells or on the external cell surface
[40-42]. Further, the conjugation reaction and subse-
quent release of the gabapentin might have converted it
to a chemically distinct metabolite or residue. The high
efficacy of this intraneurally delivered agent constructed
with gabapentin demonstrates for the first time that
delivery of a clinically efficacious small molecule thera-
peutic agent from inside the cell via an intraneural route
can achieve the same pharmacological effect as delivery
Figure 12 Axonal transport to dorsal root ganglion neurons.( a)
Delivery to rat dorsal root ganglion cells from different peripheral
sources. Section of L4 dorsal root ganglia showing retrogradely
transported FITC (green) injected intra-muscular and TRITC (red)
injected intra-plantar, in the sensory neuron cell bodies (fp -
footpad injection, ga - gastrocnemius injection) (b) higher resolution
view. Scale bars (a) = 170 μm, (b)=4 5μm.
Figure 13 WGA-dex-FITC transport to dorsal root ganglion cells.( a) Section of L4 dorsal root ganglia showing retrogradely transported FITC
in the sensory neuron cell bodies. (b) The FITC can be seen in sensory dendrites arriving at the cell. Ax - axon, DRG - dorsal root ganglion, Ne -
neuron cell body. Scale bars (a) = 150 μm, (b)=8 0μm.
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Page 11 of 26Figure 14 Demonstration of transport to C-type nociceptor cells in dorsal root ganglion. Section of rat L5 dorsal root ganglia showing
retrogradely transported FITC combined with immunohistochemistry for the specific C-fiber nociceptor marker, Peripherin. (a) - Retrogradely
transported FITC, (b) - the same field as in (a) showing cells that are immuno-positive for peripherin, (c) - overlay of (a) and (b) showing FITC is
present in the nociceptors (v - same neuron in a, b,& c). There are 26 cells seen with FITC in (a) versus 59 cells with peripherin in (b)&( c). (d)-
Two sensory neurons containing retrogradely transported FITC, a third neuron is unlabeled, (e) - the same field as in (d) showing that all three
neurons are positive for Peripherin, (f) - overlay of (d) and (e) (^ - same neuron in d, e,& f). Scale bars (a-c) = 150 μm, (d-f)=4 0μm.
Figure 15 Tissue distribution data for intramuscular [
125I]-WGA. Results are standardized by dividing all results for a given animal by the
cpm/mg in blood for that animal. This results in a dimensionless figure proportional to concentration in tissue relative to concentration in blood
for each tissue in each animal. Data are arrayed in chronological experimental sequence order as follows: (a) and (b) - incision with suture
closure and 3 day survival; (c) - similar to (a)&( b) but longer survival time; (d) - superglue seal on the incision, animals kept in a metabolic cage;
(e), (f), and (g) - the [
125I]-WGA was concentrated into one tenth the volume; (h) - large dose with 20 injection locations of 0.5 microliters each
and longer survival; (i) and (j) - ten small injections; (k) - 10 gm-cm spinal cord injury; (l)- 25 gm-cm spinal cord injury; (m) - very long survival of
10 days (multiplied by 10 to emphasize very low retention).
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roborates recent evidence that the site of action of gaba-
pentin is indeed intracellular [43].
One of the functions of retrograde axonal transport is
to allow the cell body to sample conditions at the dis-
tant axon terminus in order to obtain information on
requirements for replacement organelles, proteins, and
small molecules. Excessive hydrolysis in lysosomal trans-
port vesicles would interfere with this sampling process,
so the preservation of therapeutic molecules during axo-
nal transport in vesicles is consistent with this function.
Chronic use of axonal transport agents raises the issue
of specialized toxic effects associated with the delivery
system. In general, the amount of drug being delivered
to the axonal intracellular space will be similar to nor-
mal therapeutic delivery and will be handled by the
same clearance methods that the cell usually relies on.
The ATF will be delivered in amounts that are physiolo-
gic and will present no special accumulation risk
although there may be unintended direct intracellular
signaling effects from some ATFs that would need to be
identified. The dextran or other polymer linker could be
subject to accumulation, however it must be kept in
mind that the axon is constantly ingesting extracellular
fluid as a means of sampling the environment of the
axon terminus for presentation to the regulatory appara-
tus in the cell nucleus after transport. The cargos deliv-
ered by the endosome/lysosome system physiologically
must be degraded and removed from the cell. We did
not observe any apparent toxicity upon histological ana-
lysis of the CNS or axonal structures in any of these
experiments, however, this issue would be need to be
carefully assessed in the course of development of any
pharmaceutical for axonal delivery.
Conclusions
These studies demonstrate that intraneural delivery of
pharmaceutical agents as part of a tripartite complex
(axonal transport facilitator + polymer + multiple conju-
gated drug molecules) results in a unique distribution in
which high concentrations reach targeted CNS, auto-
nomic and peripheral nerve targets. The resulting
Figure 16 Effect of gabapentin delivered by intraneural vehicle. The effect of Gabapentin tripartite administration, to mono-neuropathic
animals, on thermal nociceptive threshold (con, contralateral; ips, ipsilateral; GPN, Gabapentin). Results are the mean ± SEM (n = 6). The
difference between the ipsilateral and contralateral side is significant from 4 days post surgery to the end of the experiment in all treatment
groups. Treatment with Gabapentin tripartite to the injured limb caused a significant elevation in paw withdrawal latency which was evident
within 2 days and lasted for a further 4 days, after which the latency returned to that of the other groups (e.g. day 12, P = 0.0049 between Dx-
GPN and GPN tripartite ipsilaterally). This effect was not observed in any other group.
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is several orders of magnitude lower than the concentra-
tion in targeted CNS and PNS tissues. This effect can be
achieved using a well tolerated and non-invasive clini-
cally applicable administration route - intramuscular
and intradermal injection.
Whilst there are additional issues to resolve before
axonal transport based medications come into regular
clinical use, their eventual development now seems rea-
listic. Previously, the relatively small number of ‘uptake
events’ per neuron for molecules like NGF has limited
their applicability for intraneural drug delivery. This
work demonstrates that a tripartite complex with a poly-
mer linker carrying large numbers of drug molecules
can amplify the pharmacological effect of each uptake
event by at least two orders of magnitude. Amplification
by an additional order of magnitude through alternative
conjugation schemes appears to be readily achievable.
The delivery to DRG neurons including nociceptors as
well as to motor column neurons has positive implica-
tions for the development of medications for pain, mus-
cle spasm, neuroprotection and anti-viral treatment. We
anticipate that intraneural pain medication will have a
significant impact on the management of pain after sur-
gery and in the treatment of patients suffering from
intractable chronic pain unresponsive to existing pain
medications. Some efficacious agents whose use is lim-
ited by systemic toxicity may be safely and effectively
delivered by an axonal transport delivery vehicle. It is
likely that anti-viral, neuroprotectant and anti-spasmodic
agents (small molecule, peptide, or nucleic acid) can also
be delivered to important locations in the nervous sys-
tem in this manner. The application of this new class of
tripartite intraneural pharmacologic vehicles also pro-
vides a novel tool for the investigation of a number of
aspects of basic neurobiology.
Methods
These are summarized in Table 1.
Synthesis and Stability (aspect A)
Chemical Methodology: Syntheses of various tripartites
(project I)
Assembly and loading of tripartite drug carriers [study 1]
We constructed a tripartite drug delivery vehicle using
carboxyl linkages to bind multiple molecules of the
selected drug to each 70,000 MW dextran molecule,
then conjugated WGA to the dextran to act as axonal
transport facilitator (ATF) (Figure 1). Efficiency of load-
ing of the polymers by drug or label molecules was
assessed with nuclear magnetic resonance (NMR) spec-
troscopy or by high pressure liquid chromatography
(HPLC) with mass spectrometry. Iterative variations of
synthetic techniques were carried out to achieve
progressively greater levels of drug loading with preser-
vation of the targeting affinity of the ATF portion of the
complex.
Carboxy modified dextran (standard loading)
(protocol 1a)
Dextran (MW 70,000; Sigma) (324 mg) was dissolved
with stirring in water (30 ml) and the solution made
basic by the addition of 2 M potassium hydroxide (50
μl). Cyanogen bromide (424 mg) was added and the
solution treated with 2 M potassium hydroxide (50 μl)
at 15 minute intervals for the next 2 hours. After stir-
ring for a further 2 hours, more cyanogen bromide (424
mg) was added and the solution treated with 2 M potas-
sium hydroxide (50 μl) every 15 minutes for a further
hour. Thesolution was then stirred at room temperature
overnight. 6-Aminohexanoic acid (5.24 g) was added
and the solution adjusted to pH 11 by the addition of
10 M potassium hydroxide. The solution was then stir-
red at room temperature for two days and the solution
adjusted to pH 2 by the addition of hydrochloric acid.
After filtration through a 0.45 μmm e m b r a n et h es o l u -
tion was concentrated with a stirred cell (membrane
MWCO 30,000) and the concentrate washed similarly
four times with water. The resulting solution was lyo-
philized to afford a colorless solid, 272 mg.
1HN M R
analysis (400 MHz, D2O) suggested a carboxy loading of
11-12%.
Carboxy modified dextran (Aminohexanoic acid) -
Upgraded loading (protocol 1b)
Dextran (MW 70,000; Sigma) (162 mg) was dissolved
with stirring in water (30 ml) and the solution made
basic by the addition of 2 M potassium hydroxide (50
μl). Cyanogen bromide (212 mg) was added and the
solution treated with 2 M potassium hydroxide (50 μl)
at 15 minute intervals for the next 2 hours. A second
portion of cyanogen bromide (212 mg) was added and
the solution treated with 2 M potassium hydroxide (50
μl) every 15 minutes for a further hour. 6-Aminohexa-
noic acid (2.62 g) was added and the solution adjusted
to pH 10.5 by the addition of 2 M potassium hydroxide.
T h es o l u t i o nw a st h e ns t i r r e da tr o o mt e m p e r a t u r ef o r
two hours and then adjusted to pH 2 by the addition of
hydrochloric acid. After filtration through a 0.45 μm
membrane the solution was concentrated with a stirred
cell (membrane MWCO 30,000) and the concentrate
washed similarly four times with water. The resulting
solution was lyophilized to afford a colorless solid, 180
mg.
1H NMR analysis (400 MHz, D2O) at 70°C sug-
gested a carboxy loading of 30%.
Carboxy modified dextran (extended chain length
linker) (L-Lysine diacetic) (protocol 1c)
Dextran (MW 70,000; Sigma) (81 mg) was dissolved
with stirring in water (15 ml) and the solution made
basic by the addition of 2 M potassium hydroxide (50
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solution treated with 2 M potassium hydroxide (50 μl)
at 15 minute intervals for the next 2 hours. A second
portion of cyanogen bromide (106 mg) was added and
the solution treated with 2 M potassium hydroxide (50
μl) every 15 minutes for a further hour. L-Lysine-Na,
Na-diacetic acid (724 mg) was added and the solution
adjusted to pH 10.5 by the addition of 2 M potassium
hydroxide. The solution was then stirred at room tem-
perature overnight and then adjusted to pH2 by the
addition of hydrochloric acid. After filtration through a
0.45 μm membrane the solution was concentrated with
a stirred cell (membrane MWCO 30,000) and the con-
centrate washed similarly four times with water. The
resulting solution was lyophilized to afford a colorless
solid, 110 mg.
1H NMR analysis (400 MHz, D2O) at 70°
C suggested a carboxy loading of 27% (81% with respect
to carboxylate).
WGA-carboxydextran conjugate (protocol 1d)
Carboxy modified dextran (80 mg) was dissolved in
water (20 ml) and the solution made basic by the addi-
tion of 2 M potassium hydroxide (50 μl). Cyanogen bro-
mide (212 mg) was added and the solution treated with
2 M potassium hydroxide (50 μl) every hour for the
next 6 hours. The solution was stirred at room tempera-
ture overnight and then concentrated with a stirred cell
(membrane MWCO 30,000) and the concentrate simi-
larly washed four times with water. After concentration
t o6m l ,W G A( 3m g )i n1 0 0m MC a C l 2/MnCl2 (4 ml)
was added and the solution stirred overnight. The mix-
ture was applied to an N-acetylglucosamine (NAcGlu)
affinity matrix column and the column washed with
water. Elution with 800 mM NAcGlu (10 ml), stirred
cell purification (MWCO 30,000) with four water
washes and lyophilization afforded bipartite as a color-
less solid, 2 mg.
WGA-carboxydextran-valacyclovir conjugate
(protocol 1e)
WGA-carboxydextran conjugate (2 mg) was dissolved
in 100 mM CaCl2/MnCl2 (1.5 ml). Valacyclovir (20 mg)
and EDC (1-Ethyl-3- [3-dimethylaminopropyl] carbodii-
mide) hydrochloride (20 mg) were added and the solu-
tion stirred at room temperature overnight. Filtration
through a 0.45 μm membrane, concentration with a stir-
red cell (membrane MWCO 30,000) with four water
washes and lyophilization afforded tripartite as a color-
less solid, 1.5 mg.
Carboxydextran-gabapentin conjugate (protocol 1f)
Carboxy modified dextran (162 mg) was dissolved in
water (15 ml). Gabapentin (200 mg) and EDC hydro-
chloride (575 mg) were added and the solution stirred
at room temperature overnight. Filtration through a
0.45 μm membrane, concentration with a stirred cell
(membrane MWCO 30,000) with four water washes and
lyophilization afforded bipartite as a colorless solid, 145
mg.
g. WGA-carboxydextran-gabapentin conjugate
(protocol 1g)
Carboxydextran-gabapentin conjugate (25 mg) was dis-
solved in water (10 ml). Cyanogen bromide (30 mg) was
added and the solution treated with 2 M potassium
hydroxide (10 μl) every hour for the next 6 hours. The
solution was stirred at room temperature overnight and
then concentrated with a stirred cell (membrane MWCO
30,000) and the concentrate similarly washed four times
with water. After concentration to 3 ml, WGA (1 mg) in
100 mM CaCl2/MnCl2 (2 ml) was added and the solution
stirred overnight. The mixture was applied to an N-acet-
ylglucosamine (NAcGlu) affinity matrix column and the
column washed with water. Elution with 800 mM NAc-
Glu (10 ml), stirred cell purification (MWCO 30,000)
with four water washes and lyophilization afforded tripar-
tite as a colorless solid, 4.5 mg.
Synthesis of superparamagnetic hydroxide free ferrite
particulate carriers [study 2] Assessment of size limits
included synthesis of hydroxide-free (non-reactive) super-
paramagnetic magnetite particles coated with dextran con-
jugated to WGA. These were capable of serving as
synthetic vectors for gene delivery and capable of identifi-
cation by electron microscopy, [
59Fe] radiolabel studies, as
well as having sufficient relaxivity contrast effect to be
detectable by microscopic MRI (magnetic resonance ima-
ging) and MR Neurographic techniques [44,45].
Precipitation of water soluble superparamagnetic
particles [protocol 2a]
Using double distilled water (not de-ionized) to make
up the reaction mixture the following steps were con-
ducted: 1.5 ml of 33% NH3 was added to 4.5 ml of hot
dH2O (to make up 7.5% NH4OH) and brought to 60°C
standing in a capped universal tube in a water bath.
1.25 gm Dextran (MW 10,000) was dissolved in 2.0 ml
of ddH2O and 225 mg FeCl3.6H2O dissolved in the dex-
tran solution. 100 mg FeCl2.4H2O is dissolved in the
Fe3/dextran solution and the mixture kept in a 60°C
water bath for two minutes before incremental addition
of 6 ml of hot 7.5% NH3 solution (60°C). The product
was left to stand in the 60°C water bath for fifteen
minutes.
The reaction product (dextran-coated ferrites) was
centrifuged three times at 1,000 g for 10 minutes and
any precipitate discarded each time. The supernatant
was applied to PD-10 columns (Pharmacia) equilibrated
with 0.1 M NaAcetate buffer, pH 6.8 with 5 mM EDTA
(ethylenediaminetetraacetic acid).
The black eluted fraction was diluted 1:3 with EDTA/
Acetate buffer then concentrated to one-tenth the initial
volume with Amicon Centriprep-100 ultrafilters. The
retentate was diluted 1:10 with EDTA/Acetate buffer
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triprep-100 ultrafilters.
Periodate conjugation of targeting agent [protocol
2b]
0.30 ml of 20 mM NaIO4 was added to the dextran
ferrite solution (approx. 1.5 ml) while stirring then
gently tumbled for 60 minutes at room temperature in
the dark. At the end of the 60-minute periodate incuba-
tion, the reaction was terminated by applying the reac-
tion mixture to the PD-10 columns equilibrated with 20
mM borate buffer (pH 8.5).
An active site blocking solution was prepared using
100 mM MnCl2/CaCl2 for WGA binding reactions to
protect the WGA binding site during the conjugation
reaction.
10 mg of the ATF protein was dissolved in 500 ml of
20 mM Na borate buffer, pH 8.5 at room temperature.
10 ml of the blocking solution was added to the pro-
tein/borate solution then 2.0 ml of oxidized magnetite
dextran mixed with 500 ml of the protein/borate solu-
tion. 20 ml of the blocking solution was added into the
2.5 ml protein-dextran-magnetite mixture and mixed
well, then incubated for 6 to 18 hours at room tempera-
ture with shaking.
After the incubation, 100 ml of 0.5 M glycine was
added to the reaction mixture and incubated for 2
hours. 250 ml of 0.25 M NaBH4 was added to the mag-
netite-dextran-protein solution and allow to stand for 60
minutes, shaking periodically to release H2 gas. At the
end of the incubation the reaction mixture was passed
through PD-10 columns equilibrated with 20 mM
HEPES buffer, pH 7.4. The eluant was diluted 1:5 with
HEPES buffer then concentrated with Centriprep-100
ultrafilters.
Affinity purification [protocol 2c]
An affinity purification step is optional and detail is
given for use with a WGA (lectin) targeting protein.
The final retentate was applied to affinity columns (N-
Acetyl-Glucosamine) (20 mM HEPES buffer), washed
with HEPES, then specifically eluted with 1 M NAcGlu
in HEPES buffer, pH 7.4. The specific eluant was passed
through PD-10 columns equilibrated with HEPES to
remove NAcGlu, Mn and Ca.
The desalted output was then diluted to a volume of
24 ml with HEPES buffer and concentrated with Centri-
prep-100 concentrators. The final retentate was steri-
l i z e db ys p i n n i n ga t5 0 0gf o ro n eh o u ri n0 . 2 2m m
centrifugal microfilters. The purified, sterilized synthetic
vector particles were stored at 4°C for use within one to
two weeks. (not be frozen or lyophilized).
DNA adhesion [protocol 2d]
The methodology for carrying out and demonstrating
DNA adhesion and uptake with these particles is
detailed elsewhere [46].
Relaxivity assessment [protocol 2e]
Phosphate buffered polyacrylamide gel phantoms (C%
= 2.7, T% = 11) were cast in test tubes after mixing
with various concentrations of WGA-dex-mag using
various different dextran lengths. The gels were used to
simulate animal tissue for MRI relaxivity testing as
described previously [47]. Gel tubes were placed in sole-
noid coils for T2 measurements in a 4.7 Tesla SISCO
MRI spectrometer. Subsequently, the gels were sub-
jected to ferrozine iron assays to verify the iron concen-
trations [48]. This resulted in relaxivity data
demonstrating the concentration needed to reduce T2
below 30 msec - which would be readily visible relative
to many other tissues with longer T2 (Figure 7).
Intracellular release from tripartite and drug activation in
cell culture (project II)
Uptake and intracellular drug release in a Valacyclovir
BHK plaque assay [study 3] In vitro comparison of the
antiviral efficacy of free valacyclovir, valacyclovir linked
to dextran and WGA-dextran-valacyclovir was tested in
ap l a q u er e d u c t i o na s s a yt oe v a l u a t et h ei m p a c to ft a r -
geting molecules on endocytosis of large drug carrying
complexes and to assess potential efficacy of drug mole-
cules released from the tripartite complex after cellular
endocytosis in a Herpes simplex virus/BHK (baby ham-
ster kidney) cell model.
Plaque reduction assays were designed via modifica-
tion of methods previously described [49,50]. The conju-
gation strategy for the valacyclovir prodrug to the
dextran backbone assured that hydrolysis of the molecu-
lar link would be required to release drug and that the
hydrolysis would release active acyclovir rather than the
inactive prodrug [51].
The virus used throughout these studies was HSV-1
strain SC16 (originally isolated from a clinical case of
Herpes labialis). This strain has been extensively charac-
terized in mice and has been previously use for studying
antiviral compounds. Viral working stocks were pro-
duced at a low multiplicity of infection in BHK-21 cells
(baby hamster kidney cells) and stored in small aliquots
at -70°C. Maintenance of BHK-21 cells was performed
using standard procedures.
The conjugate stoichiometries were approximately Dx
(70):Val = 1:50; WGA:Dx(70):Val = 2:1:50. In terms of
valacyclovir (w/w), the free Val:Dx-Val:WGA-Dx-Val
ratio is assumed to be 1:0.1:0.08 (i.e. correcting for vehi-
cle mass). Thus, 1 mg (free) = 10 mg (di-partite) = 12.8
mg (tri-partite). Therefore, stock solutions of 1 mg/ml
(free drug), 10 mg/ml (di-partite), 12.8 mg/ml (tri-par-
tite) were required to ensure equivalent valacyclovir
added for a given volume addition.
In initial range finding plaque reduction tests, the free
drug was approximately 10-fold more potent as an anti-
viral than the Dx-Val conjugate and a more suitable
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assay, whilst a range between 0-100 μg was required for
di-partite. Testing the tri-partite compound, initially a
range of 0-100 μg valacyclovir was chosen. However,
this was found to be overload (i.e. no plaques observed
at the first data point corresponding to 5 μgv a l ) .T h i s
suggested that the IC50 for the tri-partite would be
about 2.5 μg.
To ensure the addition of identical volumes in each
assay a 10-fold dilution of the free drug stock was made
to give 0.1 mg/ml.
Finally, volumes of between 0-100 μla n t i - v i r a ls o l u -
tion (equivalent to 0-100 μg valacyclovir in non-ATF
conjugated form or 0-10 μg in free form or tripartite
form) were added to wells of BHK cells infected with
HSV-1 and plaque numbers counted (in replicates of 6)
following a three day incubation.
Interaction with Axon Terminals & Intra-Axonal
Environment (aspect B)
Effects of polymer, linker and drug (project III)
We used cultured dissociated sympathetic ganglion neu-
rons to evaluate the effect of polymer size, of molecular
charge and of chemical side groups that varied the
hydrophilicity of the molecular complex upon efficacy of
uptake by neurons in open cultures.
Size Dextran-FITC [study 4] We synthesised a series of
dextran-based FITC-containing polymers coupled to
WGA. In an initial series, we evaluated the effects of dif-
ferences in dextran size on uptake by cultured sympa-
thetic ganglia. For the size trials, we incubated the
ganglia cultures with the tripartite for varying lengths of
time, then washed the cultures and examined them
using fluorescence and also backlit fluorescence
microscopy.
Charge Effects on Dextran-FITC Neuronal Uptake [study 5]
Each material was based on dextran-70. Dextran-70
was used to best illustrate the effects of the modifica-
tion rather than using dextran-10 which had more effi-
cient uptake in its native state. The charge of the
materials was created by activating the sugar mono-
mers and coupling with either a carboxyl terminated
linker or an amine terminated linker. The neutral ver-
sion was achieved by coupling a 50:50 mix of carboxyl
and amine linkers. WGA and FITC was coupled as
well. The various agents were incubated with cultured
sympathetic ganglia after which the media were
washed and evaluation was of uptake was carried out
by backlit fluorescence microscopy capable of viewing
neurite projections with or without the presence of
transported agent.
Acylation effect [study 6]We carried out various degrees
of acylation of FITC labeled dextran followed by conju-
gation with WGA in order to test the effects of
increased hydrophobicity on uptake in cultured sympa-
thetic ganglia. Once again dextran-70 was used to best
illustrate the effects of the modification rather than
using dextran-10 which had more efficient uptake in its
native state. FITC labeled, WGA-conjugated dextran-70
with no acylation was used as a control.
Effects of Axonal Transport Facilitator (ATF) (project IV)
Campenot Chamber - Comparison of physiologic vs non-
physiologic ATF [study 7] Cultured neurons grown in
compartmented Campenot chambers [52] were used to
demonstrate the direct relationship between ATF and
the ability to reach the cell body via axonal transport
(Figures 17 &18). FITC conjugated WGA was compared
to Texas Red (Sulforhodamine 101 sulfonyl chloride)
(TR) conjugated NGF in this model so that the funda-
mental efficacy and relative efficiency of derivatized
ATFs for axonal transport and for promoting transport
o ft h et r i p a r t i t ec o m p l e xc o u l db ed e m o n s t r a t e d
definitively.
See Claude et al 1982 [53] for full method including
sympathetic ganglion culture, Campenot chambers,
assessment of receptor number and saturation. We used
this experimental arrangement to compare transport of
WGA-FITC to NGF-TR (Texas Red) to assess the
impact of ATF (axonal transport facilitator) on trans-
port. We then prepared fluorescent labeled WGA-dex-
tran-FITC and NGF-dextran-TR for comparison in the
Campenot chamber model.
Use of phage display iterative processing to generate
synthetic ATFs [study 8] By combining phage display
technology with Campenot chamber technology, we
were able to explore for and identify new purely syn-
thetic ATFs. We harvested phage from the neuronal cell
body after exposing the axons in sealed chambers to
large numbers of phage variants. These phages were
reexposed to second and third tier Campenot chamber
sorting so that only well transported phage variants
were selected and their surface variant proteins ampli-
fied and characterized by standard methods.
Phage display with an M13 phage library was carried
out in a modification of the receptor panning method
that has been described in detail previously [54-56]. We
used inserted peptide sequences in a pIII library with
the format CX7C denoting 7 amino acids in a disulfide
constrained loop thereby offering 1.28 × 10
9 possible
sequences. Three rounds of standard trkA receptor pan-
ning in open (uncompartmented) dishes were carried
o u t .T h es e l e c t e do u t p u tf r o mt h et h i r dr o u n dw a s
placed in the distal axon terminus chamber in Campe-
not compartmented culture dishes. We allowed 15 min-
utes for incubation with phage at a concentration of 2.7
×1 0
10 pfu/ml for adsorptive (receptor mediated) endo-
cytosis, then washed the axon terminus chambers three
times and then incubated for an additional 2 hours
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body chamber. Cell bodies were then recovered and
phage was then isolated from the cell bodies by centrifu-
gation, amplified and passaged again by reincubation
with axon termini. After three rounds of transport, the
collected phage peptide was sequenced, synthesized and
labeled with FITC at the C-terminal end.
Once added to the side compartment it was taken up
by the distal terminal neurites and axonally transported
to the cell bodies. The peptide was coupled to the
polymer vehicle and again demonstrated axonal trans-
port to cell bodies that was blockable by colchicine as
an axonal transport inhibitor as described above.
Use of transport inhibitors to confirm axonal transport
basis of effect [study 9] We sought to assess whether
redistribution of the test agents was due to axonal trans-
port rather than diffusion across the barriers, intra-mem-
brane flow, or passive distribution and diffusion within the
axoplasm after endocytosis. To test this we evaluated the
effects of an axonal transport inhibitor on movement of
Figure 17 Campenot chamber principles for compartmented cultures. The culture dish is coated with collagen, and then the substratum is
scarified with a pin rake. A shaped Teflon gasket with silicon grease on its bottom edges is placed in the chamber over the scarified tracks.
Dissociated mouse superior cervical ganglion neurons are then plated in the central chamber. Neurite outgrowths are then confirmed as they
project into the adjacent chambers.
Figure 18 Magnified detail of cultured sympathetic ganglion cells. Ganglion cells growing in a compartmented chamber with an axon
growing across the divider into the axon terminus chamber.
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play generated ATF’-dextran (or polyethylene glycol)-
FITC - tripartite molecules from the axonal compart-
ment of Campenot chamber cultures to the cell body
compartment. These studies were conducted with and
without pre-treatment with colchicine (125 micromo-
lar) - an inhibitor of axonal transport - for one hour
prior to administering the tripartite [57,58]. The tripar-
tite complex was incubated in the distal axon chamber
of Campenot chamber cultures of sympathetic ganglia.
We assessed FITC or TR fluorescence in the cell body
chamber comparing cultures in which colchicine was
included with the tripartite to those incubated without
colchicine [53].
Effects of Intra-axonal Processing (project V)
Anti-gabapentin antibodies to demonstrate drug delivery
[study 10] To explore survival of gabapentin (1-ami-
noethyl-cyclohexane acetic acid - an analogue of GABA
- gamma-aminobutyric acid) in rapid transport axonal
vesicles, we injected the tripartite complex of WGA-
dextran-gabapentin in rat biceps muscle and used gaba-
pentin antibodies to confirm delivery of materials with
preserved antigenicity into neuron cell bodies in the
CNS after intramuscular injection in the periphery.
Antibodies to gabapentin were raised and used as a
primary against sections of rat spinal cord and DRG
excised and cryosectioned at 1, 4 and 7 days after
administration of WGA-dextran-gabapentin and of dex-
tran-gabapentin into biceps femoris muscle in rats. Sec-
ondary antibody with FITC was then evaluate by
fluorescence microscopy.
WGA-HRP to demonstrate intact delivery of enzymes
[study 11] To assess survival of enzymes during trans-
port in a primate model with axons up to 20 cm in
length, we injected microgram quantities of wheat
germ agglutinin (WGA) (Triticum vulgaris) conjugated
to horseradish peroxidase (HRP) in microliter volumes
in Macaca fascicularis epaxial (back) muscles (short
transport distance) and hypaxial (abdominal) muscles
(long transport distance). After three days, peroxidase
enzymatic amplification of transported (HRP) in sec-
tioned spinal cord with tetramethylbenzidine (TMB)
staining of the reaction product [59,60] allowed eva-
luation by back-field fluorescent microscopy. The
injections sites were also stained to accurately assess
the distribution of remaining injectate in the source
tissue.
Four adult Macaca fascicularis animals were anesthe-
tized with 25 mg/kg ketamine and 2 mg/kg xylazine
(IM) and in various combinations, erector spinae, trans-
versospinalis, or rectus abdominis muscles were surgi-
cally exposed and injected with a 5% solution of lectin
conjugated horseradish peroxidase (WGA-HRP, Sigma
Chemical Co, St. Louis, MO). To sample a wide range
of motor units while minimizing the possibility of tracer
leakage to adjacent muscles, WGA-HRP was delivered
via multiple, small intramuscular injections with either a
1 μlo r5μl Hamilton syringe. A total of 0.5 to 2.5 μl
was delivered to some various muscles (one to five
injections of 0.5 μl each). During surgery, care was
taken to preserve the integrity of the fascial membranes
separating the various muscles as intact fascial mem-
branes can form a barrier to the leakage of tracer from
injected muscle [61].
Eighteen to seventy-two hours following WGA-HRP
injection, the animals were reanesthetized with an
overdose of pentobarbital sodium and perfused
through the left ventricle with 1-2 liters of 0.9% saline,
followed first by 1-2 liters of a fixative containing 0.5%
paraformaldehyde, 2.0% glutaraldehyde, and 2.0%
sucrose in a 0.1 M phosphate buffer and second by
0.5-1.0 liters of 10% sucrose in 0.1 M phosphate. The
spinal cord was exposed, spinal nerves II-XXVI were
identified and segments IX to XXIII were removed and
stored, together with excised relevant muscles, for 1-3
d a y si na2 0 %s u c r o s es o l u t i o no f0 . 1Mp h o s p h a t ea t
4°C.
The spinal cord was cut serially in 75 μm transverse
sections on a freezing microtome. Frozen 75-100 μm
sections of the muscles were also cut in transverse,
sagittal, and coronal planes. Spinal cord and muscle sec-
tions were collected in a solution containing 30%
sucrose and 30% ethylene glycol in 0.1 M phosphate
buffer and stored for up to 1 week at 0°C.
Spinal cord and muscle tissue from all experiments
was processed with tetramethyl benzidine (TMB)
[59,62,63]. Every second or fourth section of brainstem
tissue and every fourth or sixth section of muscle was
reacted with TMB for 2-4 hours, mounted on gelatin-
coated slides, air dried, and counterstained in neutral
red. Spinal cord and muscle slides were examined in
brightfield, darkfield, or polarized light microscopy to
determine the extent of the injection site and resulting
spinal cord label. Spinal cord and muscle sections with
WGA-HRP label were photographed and traced.
Electron Microscopy to demonstrate WGA-dextran-mag-
netite in transport stream [study 12] To confirm the
location of WGA-dextran-magnetite in transport vesi-
cles in axons, distributed by axonal transport, we carried
out electron microscopy of rabbit sciatic nerve at appro-
priate time intervals for fast axonal transport after injec-
tion in gastrocnemius and anterior tibial muscles.
WGA-dextran-magnetite conjugate complex was pre-
pared, purified, filter sterilized and injected. After allow-
ing six hours to elapse, animals were sacrificed,
perfused, and their upstream ipsilateral and untreated
contralateral sciatic nerves were then excised and pre-
pared for electron microscopy [31].
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59Fe]-WGA-dex-mag
location [study 13] To additionally prove intraneural
transport we made [
59Fe]-dextran magnetite and carried
out large format autoradiography using similar adminis-
tration methods and timing as in the electron micro-
scopy experiments.
This agent was produced as in study 2 above, includ-
ing 250 microCuries of [
59Fe] in the initial ferrite nano-
particle precipitation step. The injectate for each
experiment represented a concentrate of about one
tenth of the batch of [
59Fe] particles so that 25 micro-
Curies were delivered. The [
59Fe]-WGA-dex-mag was
administered in rabbits. As in the micro MRI imaging
experiments, injection involved preparations concen-
trated to 15 mg Fe/ml injected into forearm muscula-
ture of rabbits using three sites, 50 microliters per site,
using pre-puncture with an 18 gauge needle, introduc-
tion of a Hamilton syringe for injection, then superglue
seal of the puncture site.
After a four day survival, the rabbits were sacrificed
under deep barbiturate anesthesia by intracardiac perfu-
sion with sucrose glutaraldehyde solution. The forelimb
from the ipsilateral and contralateral side was then fro-
zen, cut as an intact cross section, refrozen sealed with
cellophane and applied to X-ray film in cassettes in a
freezer at -4 degrees centigrade for 12 hours.
WGA-dex-mag MRI microscopy to demonstrate intact
magnetite during transport [study 14] Microscopic MRI
(50 micron in plane resolution) was used to demonstrate
the preservation of intact transport particles during axo-
nal transport. WGA-dextran-magnetite was injected in
rabbit gastrocnemius muscle with subsequent micro-
scopic MRI. Significant hydrolysis of the magnetite
superparamagnetic nanoparticles would have destroyed
their relaxivity (contrast effect). Rabbits were used to
p r o v i d ea no r d e ro fm a g n i t u d ei n c r e a s ei nd i s t a n c e
transported relative to rats and to assure that the area
of sciatic nerve imaged or examined was sufficiently dis-
tant from the injection site to reliably eliminate any
local spread. Use of rabbits also extended the efficacy of
microscopic MRI for evaluation of sciatic nerves in vivo
due to the order of magnitude increase in body size and
nerve size relative to rats while still accommodating the
12 centimeter inner bore size of the microscopic MRI
scanner system. In the setting of MRI, physical limits on
spatial resolution are presented by instrument system
design factors (gradient coil strength, surface coil geo-
metry) so increased animal size is the only effective
compensation.
High field micro-MRI images were obtained with a 4.7
Tesla, 33-cm SISCO system fitted with a 100 miliTesla/
meter high performance auxiliary gradient insert (12-cm
inner bore). A single turn 2 cm surface coil was placed
against the upper portion of the lower leg of 2 to 2.5 kg
rabbits. The limb was taped to the side of the support-
ing cradle to minimize motion artifacts (Figure 19). The
animals were maintained under balanced continuous
intravenous infusion of an anesthetic mixture containing
1 mg of medazolam, 1.5 mg of fluanisone, and 50 μg
fentanyl/ml at rates of 4 to 10 ml/h to achieve a deep
anesthesia which further minimized motion from
respiration.
Figure 19 Microscopic MRI silastic cuff imaging set up.( a) The rabbit is positioned on gantry outside MRI scanner with surface coil over
thigh. (b) Blow up shows the surface coil over the incision line. (c) The silastic cuff is shown in place on the tibial nerve in a cross section of the
thigh. (d) The 9161 silastic cuff is shown with three outer channels for contrast gel standards and a center channel with access slit for the nerve
to be imaged.
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echo imaging sequence. To enable the determination of
the apparent T2, multiple images of the same transverse
slice were acquired with different TEs (echo times). The
data were obtained in an interleaved manner; the vari-
able parameter (TE) was arrayed for each phase-encod-
ing step, thus averaging any effects due to motion
within the duration of the experiment.
All images were acquired with a repetition time TR =
1.5 s over a 4 × 4 cm field of view (FOV) and a 2-mm
slice thickness. Two hundred fifty-six phase-encoding
steps were used and 512 data points were acquired giv-
ing a basic in plane image resolution of 156 by 78 μm.
For image analysis the data were zero filled to 1024 by
1024 and Fourier transformed after applying a 2D Gaus-
sian filter that attenuated the high-frequency time-
domain components by 6 dB. This clarified the delinea-
tion of the very small regions of interest (ROIs) (typi-
cally 0.001 to 0.003 cm
2 for nerves) but did not
significantly change the average pixel intensities
measured.
To establish persistence of the ferrite during transport
we implanted in rabbits a four channel silastic chamber
(cast from 9161 elastomer - Dow Corning) (1 cm dia-
meter, 2 cm in length with channels left by casting the
chamber around the tips of four micropipettes) in which
three chambers were filled with polyacrylamide gels
containing various concentrations of ferrites and fourth
(with an external longitudinal slit) was placed around
the nerve (see Figures 8, 19). The silastic is completely
free of MRI signal providing a dense black background
for the imaged channel contents. The chamber was
secured in a subcutaneous location below a 2 cm dia-
meter surface coil which afforded 100 micron spatial
resolution. Spin echo imaging with the various TE at
various echo times was employed to measure T2 in the
nerve chamber and compare to the surrounding stan-
dards in a series of images and measurements as time
after intramuscular injection progressed. Comparisons
were made between the steady T2 value of nerve in
uninjected animals vs animals with prior intramuscular
injection (gastrocnemius) with the WGA-dex-Fe or
W G A - d e xa g e n t sa tv a r i o u st i m e sf r o mo n et oe i g h t
hours after injection. Rabbits were implanted, injected
and imaged under continuing intravenous general
anesthesia and then sacrificed immediately following the
imaging studies.
Injection involved preparations concentrated to 5-15
mg Fe/ml injected into calf and anterior tibial muscula-
ture using three to five sites, 50 microliters per site,
using pre-puncture with an 18 gauge needle, introduc-
tion of a Hamilton syringe for injection, then superglue
seal of the puncture site.
High resolution MRI of transport for contrast effect & par-
ticle preservation [study 15] To further confirm the axo-
nal transport nerve contrast effect at appropriate time
frames, we used serial solenoid coil imaging of the
upper arm of a rabbit after injection of WGA-dextran-
magnetite with no surgical alterations. Instead we relied
on various manipulations of pulse sequence and on
magnet parameters to accomplish nerve identification
and to allow a bright T2 signal from nerve [44,45,64].
Then, by injecting the relevant musculature, we could
observe a gradual decrease in the physiologically
expected MRI nerve image signal.
The basic method is similar to study 14 except that
the system was used for high resolution MRI of rabbits
who had the WGA-dex-mag injections rather than
micro MRI. For this purpose, we used a solenoid coil to
image the forearm of essentially as described in Howe et
al [44].
Injection involved preparations concentrated to 5-15
mg Fe/ml injected into forearm flexor musculature in
rabbits using three to five sites, 50 microliters per site,
using pre-puncture with an 18 gauge needle, introduc-
tion of a Hamilton syringe for injection, then superglue
seal of the puncture site.
Images were obtained with a 4.7 Tesla, 33-cm SISCO
system fitted with a 100 miliTesla/meter high perfor-
mance auxiliary gradient insert (12-cm inner bore). A
solenoid coil was placed around the proximal portion of
the forelimb of 2 to 2.5 kg rabbits. The limb was taped
to the side of the supporting cradle to minimize motion
artifacts. The animals were maintained under balanced
continuous intravenous infusion of an anesthetic mix-
ture containing 1 mg of medazolam, 1.5 mg of fluani-
sone, and 50 μg fentanyl/ml at rates of 4 to 10 ml/h to
achieve a deep anesthesia which further minimized
motion from respiration.
The imaging sequences included either a standard
multi-slice spin-echo imaging sequence or a multi-slice
STIR (short tau inversion recovery) sequence.
Targeting and Pharmacological Efficacy (aspect C)
Clinical Target Access (project VI)
To clarify the capability for selective targeting of neuro-
nal sub-populations, we conducted a series of evalua-
tions in rats with three types of fluorescent labeled
compounds.
For assessment of extent of access to dorsal root gang-
lion (DRG) cells and to dorsal root entry zone of Lis-
sauer regions I and II from the periphery, we injected
FITC labeled WGA in biceps femoris muscle and Tetra-
methylrhodamine isothiocyanate (TRITC) labeled WGA
in foot pad. On each of days 1-28 following injection,
dorsal root ganglia were collected, sectioned and
Filler et al. BMC Neuroscience 2010, 11:8
http://www.biomedcentral.com/1471-2202/11/8
Page 21 of 26analyzed with fluorescence microscopy for counts of
total cells and of cells with transported FITC.
Ventral horn/Intermediolateral columns [study 16] Access
to the motor anterior horn cells and to autonomic inter-
mediolateral column cells was investigated similarly by
histological evaluation of spinal cord sections after
WGA-FITC intramuscular administration in rats.
Intramuscular injection of WGA-dextran-FITC was
followed by sacrifice of the animals at 8 to 72 hours
after injection. Animals were sacrificed and perfused,
spinal cord was excised, roots were counted, and appro-
priate levels were then sectioned, mounted and stained
for histological analysis by fluorescence microscopy.
This followed the methodology of older studies [65], but
used the larger tripartite complex being evaluated for
drug delivery to assure that it would reach the expected
and desired targets.
Dorsal Root Entry Zone [study 17] To assess access to the
dorsal root entry zone Lissauer regions I and II from the
periphery, we injected Tetramethylrhodamine isothio-
cyanate (TRITC) labeled WGA in biceps femoris mus-
cle, gastrocnemius, anterior tibialis and in foot pad.
Spinal cord was sectioned and analyzed with fluores-
cence microscopy for TRITC.
The duration of time to sacrifice after injection was
extended to 24 - 72 hours and the ipsilateral dorsal root
entry zone was assessed for evidence of filling of the
proximal axons of dorsal root ganglion cells.
Foot pad/biceps to Dorsal Root Ganglion [study 18] For
assessment of extent of access to dorsal root ganglion
(DRG) cells and to dorsal root entry zone of Lissauer
regions I and II from the periphery, we injected FITC
labeled WGA in biceps femoris muscle and Tetra-
methylrhodamine isothiocyanate (TRITC) labeled WGA
in foot pad. On each of days 1-28 following injection,
dorsal root ganglia were collected, sectioned and ana-
lyzed with fluorescence microscopy for counts of total
cells and of cells with transported FITC. This allowed
for assessment of the degree to which different cell
populations could be accessed from the two different
types of injection site.
Peripherin labeling for verification of access to nociceptor
neurons [study 19] In order to demonstrate that the cells
in the dorsal root ganglia reached were nociceptors, we
used post-staining with peripherin antibodies [66] to
identify nociceptor neurons to look for colocalization
with neurons labeled by tripartite WGA-dex-FITC
injected in the periphery.
Distinctive Pattern of Distribution (project VII)
Whole body distribution - [
125I]-WGA, [
125I]-NGF, [
59Fe]-
WGA-dex-mag [study 20] To explore the whole body and
tissue distribution of axonally targeted agents and to
identify the impact of tripartite design factors on the
distribution, we injected [
125I] labeled wheat germ
agglutinin (WGA), [
125I] labeled nerve growth factor
(NGF), or dextran coated 5-15 nanometer [
59Fe]-magne-
tite (ferrite) particles [46,67] conjugated to WGA
(WGA-dex-mag) in hindlimb and forelimb musculature
of rats with varying doses and measured concentrations
in seventy tissues after survival times varying from one
to five days.
Identification of experimental factors affecting
trans-neuronal distribution (protocol 20a)
[
125I]-WGA (wheat germ agglutinin) was obtained
from ICN (specific activity = 25 mCi/mg) and concen-
trated with Centricon-10 (Amicon) centrifugal ultrafil-
ters to a concentration of 333 μg/ml (8.9 μM) with a
specific activity of 25 μCi/μgm in 0.1 M phosphate buf-
fer, pH 7.4 (~7 μCi/μl). Twenty three rats (200-300 gm)
were given water with Lugol’s iodine (0.05% KI in
water) for at least 3 days prior to the injection and were
maintained on this water, one animal per cage, during a
survival period of two to ten days in grid floor cages
with twice daily changes of litter. Some animals were
maintained in Nalgene metabolic cages in order to pre-
vent ingestion of [
125I] contaminated urine and feces
and to permit daily collection of urine and feces for
assay.
Concentrated [
125I]-WGA injected percutaneously into
rat forearm or hindlimb muscle in various microliter
quantities. Introduction of the injectate was done in sev-
eral different ways: 1) by incision access to muscle with
suture closure, 2) by incision and using methacrylate to
seal the incision site, 3) by skin puncture with an 18
g a u g en e e d l ef o l l o w e db yH a m i l t o nn e e d l ei n t r o d u c t i o n
then methacrylate closure of the puncture site, 4) percu-
taneous by needle puncture followed by methacrylate
closure. The puncture sites (in 2, 3, & 4) were sealed
with methacrylate superglue immediately upon removal
of the needle. This measure was taken to limit oral
uptake by licking of the wound.
Intramuscular targets were varied to include forearm
(15 animals), calf (2 animals), or calf and anterior com-
partment of distal lower extremity (7 animals) or in pos-
terior thigh muscle mass (4 animals) to assess sites
which might offer either greatest muscle volume (thigh)
or highest innervation ratio of axons and muscle spin-
dles per unit of muscle (forearm) To compare with
other models for tracer administration, distribution was
assessed after handpad skin, tongue, vibrissal and cere-
bral cortex injections.
For the intramuscular injections, Hamilton syringes
partially loaded with paraffin oil were used to obtain
precise injection quantity. Under general anesthesia
induced with intraperitoneal barbiturate, the site of
injection was shaved, the skin was either opened over 3-
4 mm with a scalpel for direct visualization of the target
muscle or first punctured with a beveled 18 gauge
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into the selected muscle mass. Injection sites were either
in the forearm or calf. Injections were done slowly, deli-
vering volumes of 0.1-0.5 μl in a series of locations in a
selected muscle (without removing the needle from the
muscle) over five minutes to minimize back diffusion.
The largest total volume of injection was 6 μlf o rf o r e -
arm sites and 10 μl for hindlimb sites.
In animals used in nerve intervention studies, the
nerve was identified surgically under deep barbiturate
anesthesia using an operating microscope. The nerve
was either firmly crushed in forceps or crushed and
then suture ligated with the lesion placed at a point at
least two centimeters proximal to the muscle to be
injected. After assuring hemostasis, the wound was then
sewn closed and sealed over with methacrylate glue and
the tracer injection then carried out via a separate
puncture site which was also sealed with methacrylate
glue.
The duration of time for distribution of the injected
agent was varied from three to ten days after which ani-
mals were sacrificed with intraperitoneal barbiturate
overdose, and, after withdrawing a blood sample by
intracardiac puncture, perfused with phosphate buffered
saline (PBS) to clear virtually all of the blood from the
vasculature, and then with cold PBS paraformaldehyde
solution. After perfusion, the animals were dissected and
70 different tissue specimens including lymph nodes,
liver, lung, muscle, ipsilateral and contralateral periph-
eral nerve, spinal root/dorsal ganglia, and various spinal
cord segments were collected.
The various tissues were sealed immediately in micro-
fuge tubes for gamma counting with a Beckman Bio-
Gamma counter within 48 hours of the time of perfu-
sion. After counting, the samples, which remained in
sealed microfuge tubes, were weighed with a Sartorius
microgram balance. For specimens above 10 milligrams,
an average standard weight for the microfuge tube was
subtracted from the total weight, while for specimens
below 10 milligrams, the specimen was removed from
the tube for weighing.
The biodistribution trials were varied (as noted above)
to assess optimal technique and to explore the effect of
dosage and survival time (Figure 15). The variables
explored include the dose, site, and technique of injec-
tion, as well as survival time, and animal maintenance
conditions. For each animal, the raw counts per minute
from each tissue sample was divided by the weight of
that sample, thus yielding figures of cpm/mg for each
tissue. These raw distributions can be compared from
animal to animal, but to emphasize differences in the
pattern of distribution rather than differences in pure
magnitude, the results for each animal were standar-
dized for comparison by dividing all results for a given
animal by the cpm/mg in blood for that animal. This
results in a dimensionless figure proportional to concen-
tration in tissue relative to concentration in blood for
each tissue in each animal.
Data are arrayed in chronological experimental
sequence order. Experiments (a)a n d( b) used incision
with suture closure and 3 day survival - these had rela-
tively high distribution to liver and kidney apparently
related to leakage and licking of the wound site, c is
similar but used a longer survival time - this resulted in
higher DRG accumulation, and lower liver and kidney
levels apparently due to progressive metabolism after
the wound had healed with no ongoing ingestion. In
(d), a superglue seal was used on the incision and ani-
mals were kept in a metabolic cage to minimize inges-
tion of any excreted tracer - this resulted in a relatively
higher level of nerve and DRG tracer, and very low dis-
tribution in liver, kidney, or stomach. In (e), (f), and (g),
the [
125I]-WGA was concentrated into one tenth the
volume and this also decreased the liver, kidney and
stomach levels apparently because the smaller volumes
decreased leakage through the healing wound - this also
resulted in much higher levels of delivery to nerve and
DRG apparently because of a decrease in leakage of the
injectate from the muscle into sub-cutaneous non-
innervated areas as well ((g) was performed with a low
dose and the results were multiplied by 50 for purposes
of visualization on this graph). Hindquarter injections
((h)t o( m)) were more convenient for multiple injec-
tions because of the larger available muscle mass com-
pared to forelimb in these animals. In (h), a large dose
with 20 injection locations of 0.5 microliters each,
longer survival led to higher DRG concentration relative
to nerve. In (i)a n d( j), ten small injections were done
resulting in greater widespread distribution in the mus-
cle as well as good retention in the muscle resulting in
the highest nerve and DRG distributions obtained. In
(k), a 10 gm-cm spinal cord injury was applied and in
(l), a 25 gm-cm spinal cord injury was applied - the
total amount transported was decreased at 10 gm-cm so
that the amounts are multiplied by 5 to yield visible
graph data even though the typical transport distribu-
tion was still seen, however at a 25 gm-cm injury, little
or no transport occurred (liver, kidney and stomach dis-
tribution appear increased because of the multiplication
for visibility purposes). In (m), the very long survival of
10 days shows evidence of eventual metabolism out of
the nerve and DRG (multiplied by 10 to emphasize the
differential distribution despite overall very low
retention).
[
125I]-NGF studies to evaluate effect of ATF on dis-
tribution (protocol 20b)
Similar methodology was used for [
125I]-NGF (nerve
growth factor) using 4 day survival, hindlimb injections,
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injection and superglue seal in rats.
[
59Fe]-WGA-dex-magnetite to assess effects of size
on distribution (protocol 20c)
The [
59Fe]-WGA-dex-mag was administered in rab-
bits. As in the MRI imaging experiments, injection
involved preparations concentrated to 5-15 mg Fe/ml
injected into calf and anterior tibial musculature using
three to five sites, 50 microliters per site, using pre-
puncture with an 18 gauge needle, introduction of a
Hamilton syringe for injection, then superglue seal of
the puncture site. This agent was produced as in study
2 above, but including 250 microCuries of [
59Fe] in the
initial ferrite nanoparticle precipitation step. The injec-
tate for each experiment represented a concentrate of
about one tenth of the batch of [
59Fe] particles so that
25 microCuries were delivered.
Gamma camera imaging of [
131I]-WGA to evaluate local
injection effects [study 21] To compare amounts trans-
ported versus amounts remaining at the site of injection
for purpose of radiolabel imaging, we injected [
131I]-
WGA in the gastrocnemius and anterior tibial compart-
ment of rabbits, then imaged at intervals with a gamma
camera.
WGA was periodate labeled with [
131Iodine], washed
and concentrated in centrifugal ultrafilters, then injected
in the forearm muscles of rabbits. Injection were by
Hamilton syringe involving an 8 microCurie injection as
two 1.0 microliter injections, a 24 microCurie injection
as three injections of 2 microliters and a 60 microCurie
injection as five injections of 3.0 microliters. The injec-
tion sites were sealed with superglue. After the elapse of
four days, the animals were placed deep barbiturate
anesthesia and then imaged in a clinical gamma camera.
[
14C]-Gabapentin for evaluation of distribution of axonally
transported gabapentin [study 22] To document the effi-
cacy of the carrier for delivery of a small molecule phar-
maceutical in vivo, we prepared [
14C]-labeled gabapentin
and conjugated it to polymer without ATF and to poly-
mer conjugated to ATF, administered these by intra-
muscular injection, then counted various ipsilateral and
contralateral muscle and nerve tissues.
The use of radiolabeled [
3H]-gabapentin has played an
important role in studies of gabapentin localization
[68,69]. We used [
14C]-gabapentin [70] for distribution
studies essentially as in study 18 above comparing [
14C]-
gabapentin-dextran to WGA-dextran- [
14C]-gabapentin
to assess the impact of the ATF on resulting gabapentin
distribution. We chose to use [
14C]-gabapentin rather
than [
3H]-gabapentin because of the expectation of less
exchange of the labeled carbon relative to exchange of a
labeled hydrogen with other molecules and also to facili-
tate gamma counting in dissected tissues due to the
greater energy of the gamma emission.
Paw withdrawal latency for clinical efficacy evaluation in
reduction of hyperalgesia [study 23] To evaluate poten-
tial clinical efficacy for analgesia in vivo, an affinity puri-
fied agent comprising WGA-dextran-gabapentin was
used in a well characterized hyperalgesia model [71]. In
each of three repetitions of the experiment, groups of
six rats had one of four treatments: injection of into the
muscle and paw of the affected hindlimb of (1) - the full
tripartite agent (WGA-dextran-drug), (2) - dextran-drug
with no axonal transport facilitator or (3) - an equiva-
lent dose of free drug or (4) - tripartite agent injected
subcutaneously in the cervical fat pad for systemic deliv-
ery. Total doses of gabapentin were 75 micrograms in
adult 200 gm Sprague-Dawley rats. Paw withdrawal
latency in the ipsilateral and unaffected contralateral
limb was measured (a total of 72 animals).
The molecular complex (WGA-dextran-gabapentin)
was configured to deliver the anticonvulsant, gabapentin,
to selected dorsal root ganglia by retrograde axonal
transport after injection into peripheral tissue innervated
by the target nerves. The efficacy of this agent was eval-
uated in vivo using the chronic constriction injury
model of neuropathic pain. Paw withdrawal latency
(PWL) to thermal stimuli was measured in the ipsilat-
eral and contralateral limbs. Injection of the ATF drug
complex (total gabapentin dose; 75 mg/200 gm rat) or
relevant control was into hindlimb muscle and paw with
superglue seal of injection site. Animals were evaluated
for PWL prior to surgery, on the date of surgery, and at
two day intervals for twenty five days.
All animal work was carried out under strict compli-
ance with the relevant Institutional Review Board or
Home Office License requirements at the various insti-
tutions involved in the work.
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